Fig. 4.

Progression-free survival (PFS) by subgroup according to (a) IMWG frailty score, (b) age, (c) number of prior regimens, (d) baseline disease status, (e) cytogenetic risk and (f) modified cytogenetic risk. ^aClinical relapse was defined as disease recurrence with CRAB (i.e., calcium elevation, renal insufficiency, anemia, and bone abnormalities) symptoms. ^bParaprotein relapse was defined as disease recurrence with elevated M-protein levels but without CRAB symptoms. ^cStandard-risk was defined as the absence of high-risk cytogenetic abnormalities. ^dHigh-risk was defined as the presence of ≥ 1 of t(4;14), t(14;16), or del(17p). ^eModified standard-risk was defined as the absence of expanded high-risk cytogenetic abnormalities. ^fExpanded high-risk was defined as the presence of ≥ 1 of t(4;14), t(14;16), or del(17p), and/or 1q21 gain. CI, confidence interval; IMWG, International Myeloma Working Group; Int, intermediate; NR, not reached